Amgen is getting down with Disco Pharmaceuticals, commissioning the German outfit to work on cancer therapies focused on a ...

Gilead Sciences has found a shiny new package for one of its cancer assets, inking a research pact worth up to $300 million ...

Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR ...

A bevy of other companies also brought in money on Thursday, including Alveus Therapeutics, Diagonal Therapeutics, ...

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...

Amgen has bought cancer biotech Dark Blue Therapeutics in a deal that could be worth as much as $840mn, marking the latest ...

Johnson & Johnson on Monday announced a $3.1 billion deal to buy privately-held cancer biotech Halda Therapeutics, the latest in a cavalcade of biotech acquisitions as the sector has heated up over ...

PRINCETON, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the ...

Moleculin Biotech, Inc. has announced progress regarding its drug Annamycin, designed to eliminate the cardiotoxicity often associated with anthracyclines used in cancer treatments, especially in ...

Lehi, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, September 3, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to ...

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation ...